GBA's "2021 Stock Phantasma"

When I grew up and there was a big snow storm I was so happy. On went the AM radio to that local station that just said all the school closings and you waited... and waited and waited until YES SNOW DAY!

It's part of being a child. This is a Chinese authority like decision the NYC school district Boooooo De Baldsio BOOOOOOOOOOOO)
 
IS THIS WHAT THEY MEANT MORE WILL CHANGE IN THE NEXT YEAR THAN THE LAST TWENTY!!! STOCKS WILL FALL, ALL YOUR MONEY WILL BE STOLEN BY THE GOVERNMENT NEW TAXES RUIN A COUNTRIES GROWTH //MASS HYSTERIA IN THE STREETS A LA COLOMBIA...

AND NO SNOW DAYS FOR KIDS.
 
BioLineRx data make 'strong case' for motixafortide approval, says Oppenheimer 13:38 BLRX

After BioLineRx announced top line results from the Phase 3 GENESIS trial, Oppenheimer analyst Mark Briedenbach noted that the new data showed that 70% of patients achieved optimal stem cell yields after less than or equal to two apheresis sessions and make a "strong case" for motixafortide's approval. The analyst, who believes the data could support a new drug application filing in the first half of 2022, reiterate his Outperform rating and $10 price target on BioLineRx shares.

Show Related Items >>… BioLineRx price target raised to $10 from $5 at Maxim 13:28 BLRX Maxim analyst Jason McCarthy raised the firm's price target on BioLineRx to $10 from $5 and keeps a Buy rating on the shares after the company announced top-line results from the GENESIS Phase 3 trial evaluating lead clinical candidate, Motixafortide, in combination with granulocyte colony stimulating factor for hematopoietic stem-cell mobilization for autologous bone marrow transplantation in multiple myeloma patients.
 
vanzandt said:
I looked at it Stoney. It's interesting. They seem to be improving, but I don't how much money they have. I read the latest report and I think all they have is a $5M line of revolving credit. That's not much.
The old guy, I guess he's the one that founded the company, exercised 400,000 shares and the way I read it, he had to pledge them for collateral. (?) It was a bunch of mumbo-jumbo**** (edit below) that I couldn't figure out.

Their products sound really cool. You said you liked them. They're from your neck of the woods.
I guess this one will depend on the CEO (not the founder).
You're right though, I don't think it'll go much lower. Unless they go bankrupt, but sales look to be rising.

edit...
Figure this one out Stoney:

****Restricted stock issued as consideration to Reporting Person for Reporting Person's pledge to Registrant's secured lender on behalf of Registrant, providing collateral support for Registrant's credit facility. The transaction closed on March 11, 2021.

Sounds like they have a problem with cashflow that some bank somewhere doesn't like.
More...

Stoney!
Up 50%
 
The top iPhone and iPad apps on App Store
The top iPhone and iPad apps on Apple App Store for week ending 5/2/21

By The Associated Press
May 4, 2021, 5:07 PM
• 2 min read


Top Free iPad Apps:

1. Hair Challenge, Rollic Games

2. Suspects: Mystery Mansion, Wildlife Studios

3. YouTube: Watch, Listen, Stream, Google LLC

4. Hair Dye!, Crazy Labs

5. ZOOM Cloud Meetings, Zoom

6. Roblox, Roblox Corporation

7. Netflix, Netflix, Inc.

8. Slice It All!, Voodoo

9. High Heels!, Zynga Inc.

10. Disney+, Disney
 
Why Me Van. Up 50% idea. My idea. I just missed.

World’s most vaccinated nation reintroduces curbs to counter surge in COVID-19 cases
  • Seychelles with the highest COVID-19 vaccination rate in the world has reimposed COVID-19 restrictions as infections rise, Bloomberg reports.
  • The new social curbs are similar to those that were in force at the end of 2020 and include the measures to close schools and suspend sporting events for two weeks.
  • The Indian Ocean archipelago which has a population of approximately 98,000 has fully vaccinated ~62.2% of its eligible population compared to 55.9% for Israel, the next frontrunner in COVID-19 vaccination.
Ayyyyy, Another one of my $1.00 ideas-->

DTEA
4.37K followersDAVIDsTEA Inc.
3.22
-0.27(-7.74%)
4:00 PM 05/04/21
Pre-Market:$3.80+0.58(+18.01%)<----------------
 
Pfizer price target raised to $40 from $36 at JPMorgan

Van 3 of our best calls from the last thread! ) ) )

1.Trane raises FY21 adjusted EPS view to $6.00 from $5.30-$5.50, consensus $5.49

2. XPO Logistics price target raised to $170 from $150 at Citi


3. VMC
Vulcan Materials
$189.20

+9.38(+5.22%)
 
Under Armour upgraded to Buy from Neutral at UBS

WideOpenWest upgraded to Buy from Hold at Truist 06:08 WOW

Gross!> Nestle creates pea milk brand to take on Oatly in Europe, FT reports
 
Under Armour upgraded to Overweight from Equal Weight at Barclays 05:59 UAA, UA Barclays analyst Adrienne Yih upgraded Under Armour to Overweight from Equal Weight with a price target of $34, up from $25, following the company's Q1 results. The analyst sees a "significant positive inventory inflection," a return to "high-quality" sales growth in North America, and opportunity for multiyear operating margin expansion from current levels. Under Armour has completed much of "heavy lifting" in terms of right-sizing inventory and exiting undifferentiated /off-price doors, and is now positioned to focus on full-price brand rebuilding from a much healthier base, Yih tells investors in a research note.

VSE Corp. initiated with a Buy at B. Riley 05:26 VSEC B. Riley initiated coverage of VSE Corp. with a Buy rating and $61 price target.

Piper Sandler 'strongly' encourages investors buy Aziyo Biologics 04:58 AZYO Aziyo Biologics reported Q1 results that beat estimates and based on the Q1 performance, management raised its revenue outlook for the full year, which looks achievable given the "strong momentum" in its key core franchise, Piper Sandler analyst Matt O'Brien tells investors in a research note. The analyst believes Aziyo's multi-product offering is gaining traction across each vertical and that this momentum will continue through the remainder of this year and into 2022. He's been surprised by the pullback in the stock in recent weeks and "strongly" encourages investors to "step up at these levels." O'Brien reiterates an Overweight rating on Aziyo Biologics with a $20 price target.
 
You must log in or register to reply here.
Back
Top